Chardan Capital Markets Raises Price Target on Amicus Therapeutics (FOLD); Reiterates Buy

November 29, 2016 8:31 AM EST
Get Alerts FOLD Hot Sheet
Price: $5.32 -0.93%

Rating Summary:
    8 Buy, 2 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 30 | Down: 30 | New: 23
Trade FOLD Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with's Ratings Insider Elite. Get your Free Trial here.

Chardan Capital Markets reiterated a Buy rating on Amicus Therapeutics (NASDAQ: FOLD), and raised the price target to $16.00 (from $15.00), as the company updates the US regulatory approval pathway for Galafold.

Analyst Gbola Amusa commented, "Yesterday, after market close, Amicus provided an update on the US regulatory approval pathway for Galafold, a first-in-class small molecule chaperone therapy for Fabry disease. After discussions with the FDA, including an in-person Type B meeting, the FDA acknowledged that reducing kidney globotriaosylceramine (GL-3) is currently not considered a basis for an accelerated approval. Following on the FDA interaction, Amicus newly plans to perform a 12-month placebo-controlled pivotal cross-over study in treatment-naive Fabry disease patients with gastrointestinal (GI) symptoms, with diarrhea assessment based upon FDA irritable bowel syndrome guidelines as the primary endpoint. Amicus is working with the FDA to finalize the clinical protocol and plans to initiate enrollment in 2017, with data expected in 2019."

For an analyst ratings summary and ratings history on Amicus Therapeutics click here. For more ratings news on Amicus Therapeutics click here.

Shares of Amicus Therapeutics closed at $8.32 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS Change, Analyst PT Change

Related Entities

Chardan Capital Markets, Gbola Amusa

Add Your Comment